Enhancement of MHC class I binding and immunogenic properties of the CTL epitope peptides derived from dengue virus NS3 protein by anchor residue replacement

Dengue Bulletin

Volumn 32, Issue , 2008, Pages 99-109

  Masaki, Hideyuki ^a   Fujii, Yoshiki ^b,c   Irimajiri, Kiyohiro ^a   Tomura, Takanori T ^a   Kurane, Ichiro ^b,c  

^a KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

^c UNIVERSITY OF TSUKUBA   (Japan)

Author keywords

Affinity; Anchor residue; Binding motif; CTL epitope; Dengue virus; Immunogenicity; MHC class I

Indexed keywords

MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; NONSTRUCTURAL PROTEIN 3;

AMINO ACID SUBSTITUTION; ANIMAL CELL; ANIMAL EXPERIMENT; ANTIGEN BINDING; ARTICLE; BINDING COMPETITION; CARBOXY TERMINAL SEQUENCE; CD8+ T LYMPHOCYTE; CYTOTOXIC T LYMPHOCYTE; DENGUE VIRUS; EPITOPE MAPPING; FEMALE; IMMUNOGENICITY; MOUSE; NONHUMAN; STRAIN DIFFERENCE;

DENGUE VIRUS; DENGUE VIRUS GROUP; MURINAE; MUS;

EID: 70350055208     PISSN: 1020895X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Gotch F, Gallimore A, McMichael A. Cytotoxic T cells - protection from disease progression - protection from infection. Immunol Lett. 1996; 51: 125-128 (Pubitemid 26227482)
2. Kast WM, Melief CJ. In vivo efficacy of virus-derived peptides and virus-specific cytotoxic T lymphocytes. Immunol Lett. 1991; 30(2): 229-232
3. Melief CJ, Kast WN. T-cell immunotherapy of cancer. Res Immunol. 1991; 142(5-6): 425-429
4. Germain RN, Margulies DH. The biochemistry and cell biology of antigen processing and presentation. Annu Rev Immunol. 1993; 11: 403-450 (Pubitemid 23115014)
5. Matsumura M, Fremont DH, Peterson PA, Wilson IA. Emerging principles for the recognition of peptide antigens by MHC class I molecules. Science. 1992; 257: 927-934
6. Townsend A, Bodmer H. Antigen recognition by class I - restricted T lymphocytes. Annu Rev Immunol. 1989; 7: 601-624 (Pubitemid 19138026)
7. Bakker ABH, Van der Burg SH, Huijbens RJF et al. Analogues of CTL epitopes with improved MHC class-I binding capacity elicit antimelanoma CTL recognizing the wild-type epitope. Int J Cancer. 1997; 70: 302-309
8. Baratin M, Kayibanda M, Ziol M et al. Amino acid modifications in the wild type sequence p53 232-240 overcome the poor immunogenicity of this self tumour epitope. J Pept Sci. 2002; 8(7): 327-334 (Pubitemid 34784924)
9. + CTL peptide epitope variant that possesses enhancede MHC class I binding and immunogenic properties. J Immunol. 1998; 160: 2433-2441 (Pubitemid 28119928)
10. Parkhurst MR, Salgaller ML, Southwood S et al. Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A0201 - binding residues. J Immunol. 1996; 157(6): 2539-2548 (Pubitemid 126450467)
11. Petersen TR, Buus S, Brunak S, Nissen MH, Sherman LA, Claesson MH. Identification and design of p53-derived HLA-A2 - binding peptides with increased CTL immunogenicity. Scand J Immunol. 2001; 53: 357-364 (Pubitemid 32275692)
12. Thompson LW, Garbee CF, Hibbitts S et al. Competition among peptides in melanoma vaccines for binding to MHC molecules. J Immunother. 2004; 27(6): 425-431 (Pubitemid 39447350)
13. Halstead SB. Epidemiology of dengue and dengue hemorrhagic fever. In: Gubler DJ, Kuno G, editors. Dengue and dengue hemorrhagic fever. Oxon: CAB International, 1997. pp. 23-44.
14. Gubler DJ. Dengue and dengue hemorrhagic fever. Clin Microbiol Rev. 1998; 11(3): 480-496
15. Thein S, Aung MM, Shwe TN et al. Risk factors in dengue shock syndrome. Am J Trop Med Hyg. 1997; 56(5): 566-572 (Pubitemid 27230081)
16. + T-cell response to dengue virus. J Virol. 1996; 70(10): 6540-6546 (Pubitemid 26307358)
17. + T-cell clones specific for the dengue virus NS3 protein: flavivirus cross-reactivity and influence of infecting serotype. J Virol. 1999; 73(1): 398-403. (Pubitemid 28565383)
18. + cytotoxic T lymphocyte (CTL) clones. Recognition of NS3 amino acids 500 to 508 by CTL clones of two different serotype specificities. J Immunol. 1995; 154(3): 1287-1295
19. Mathew A, Kurane I, Green S et al. Predominance of HLA-restricted cytotoxic T-lymphocyte responses to serotype - cross-reactive epitopes on nonstructural proteins following natural secondary dengue virus infection. J Virol. 1998; 72(5): 3999-4004. (Pubitemid 28188703)
20. Mongkolsapaya J, Dejnirattisai W, Xu X-n et al. Original antigenic sin and apoptosis in the pathogenesis of dengue hemorrhagic fever. Nat Med. 2003; 9(7): 921-927
21. Simmons C, Dong T, Chau NV et al. Early T-cell responses to dengue virus epitopes in Vietnamese adults with secondary dengue virus infections. J Virol. 2005; 79(9): 5665-5675 (Pubitemid 40548235)
22. Rammensee H-G, Friede T, Stevanovic S. MHC ligands and motif: first listing. Immunogenetics. 1995; 41(4): 178-228.
23. d - restricted antigenic peptides share a simple binding motif. J Exp Med. 1991; 174: 603-612
24. Masaki H, Fujii Y, Irimajiri K, Munakata H, Tomura T, Kurane I. Modification of the anchor residue to MHC class I augments CTL-inducing ability of epitope peptides derived from dengue virus NS3 protein. Dengue bulletin. 2006; 30: 171-176 (Pubitemid 47489922)
25. Kozhich AT, Caspi RR, Berzofsky JA, Gery I. Immunogenicity and immunopathogenicity of an autoimmune epitope are potentiated by increasing MHC binding through residue substitution. J Immunol. 1997; 158: 4145-4151 (Pubitemid 127483913)
26. Sette A, Vitiello A, Reherman B et al. The relationship between class I binding affinity and immunogenicity of potential cytotoxic T cell epitopes. J Immunol. 1994; 153: 5586-5592.
27. Lipford GB, Bauer S, Wagner H, Heeg K. Peptide engineering allows cytotoxic T-cell vaccination against human papilloma virus tumour antigen, E6. Immunology. 1995; 84(2): 298-303.
28. b - low affinity, high affinity, and covalently-bound peptides in antitumor vaccination. Immunol Lett. 1999; 70(1): 21-28
29. Tourdot S, Oukka M, Manuguerra JC et al. Chimeric peptides: a new approach to enhancing the immunogenicity of peptides with low MHC class I affinity: application in antiviral vaccination. J Immunol. 1997; 159(5): 2391-2398 (Pubitemid 127681032)
30. Vierboom MP, Feltkamp MC, Neisig A et al. Peptide vaccination with an anchor-replaced CTL epitope protects against human papillomavirus type 16- induced tumors expressing the wild-type epitope. J Immunother. 1998; 21(6): 399-408.
31. Oldstone MBA, Lewicki H, Borrow P, Hudrisier D, Gairin JE. Discriminated selection among viral peptides with the appropriate anchor residues: implications for the size of the cytotoxic T-lymphocyte repertoire and control of viral infection. J Virol. 1995; 69(12): 7423-7429
32. Ruppert J, Sidney J, Celis E, Kubo RT, Grey HM, Sette A. Predominant role of secondary anchor residues in peptide binding to HLA-A2.1 molecules. Saibo. 1993; 74: 929-937
33. Sarobe P, Pendleton CD, Akatsuka T et al. Enhanced in vitro potency and in vivo immunogenicity of a CTL epitope from hepatitis C virus core protein following amino acid replacement at secondary HLA-A2.1 binding positions. J Clin Invest. 1998; 102(6): 1239-1248 (Pubitemid 28436284)